Kazia Therapeutics Limited filed this 6-K to disclose its half-year 2025 financial results, R&D progress, financing, and Nasdaq compliance status.
Key takeaways
For the half-year ended 31 December 2025, the Consolidated entity posted a GAAP net loss after tax of $12,552,490, compared to $10,453,811 in the same period of 2024.
As of 31 December 2025, the Consolidated entity held cash and cash equivalents of $69,459,980, up from $4,344,691 as of 30 June 2025.
On 18 December 2025, Nasdaq confirmed the company had regained compliance with Listing Rule 5550(b), allowing its ADSs to continue trading on the Nasdaq Capital Market.
In December 2025, the company completed a PIPE financing raising net proceeds of approximately $46.5 million to support clinical development of lead programs including paxalisib.
During the half-year, lead asset paxalisib was advanced into multiple breast cancer clinical settings, with positive early efficacy data reported across TNBC and HER2-positive metastatic breast cancer.
No material events impacting future operations were disclosed for the period after 31 December 2025 through the report date of 16 March 2026.